A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation

Transplant International

Volumn 29, Issue 3, 2016, Pages 369-380

  Liese, Juliane ^a   Peveling Oberhag, Jan ^a   Doering, Claudia ^a   Schnitzbauer, Andreas A ^a   Herrmann, Eva ^a   Zangos, Stephan ^a   Hansmann, Martin L ^a   Moench, Christian ^b   Welker, Martin W ^a   Zeuzem, Stefan ^a   Bechstein, Wolf O ^a   Ulrich, Frank ^a,c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Westpfalz Klinikum GmbH   (Germany)

^c Klinikum Wetzlar   (Germany)

Author keywords

biomarker; hepatocellular carcinoma; liver transplantation; microRNA; tumour recurrence

Indexed keywords

ALPHA FETOPROTEIN; MICRORNA; MICRORNA 1260; MICRORNA 140; MICRORNA 214; MICRORNA 3187; MICRORNA 3188; MICRORNA 3197; MICRORNA 371; MICRORNA 4284; MICRORNA 455; MICRORNA 494; MICRORNA 939; MICRORNA LET 7D; MICRORNA LET 7I; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; BIOINFORMATICS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLASSIFICATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MILAN CRITERIA; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; UPREGULATION; VALIDATION PROCESS; AGED; CARCINOMA, HEPATOCELLULAR; DNA MICROARRAY; LIVER NEOPLASMS; METABOLISM; POSTOPERATIVE COMPLICATION; TUMOR RECURRENCE; VALIDATION STUDY;

ADULT; AGED; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 84958551974     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12733     Document Type: Article

References (52)

1. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907.
2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA,. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817.
3. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557.
4. Strong RW,. Transplantation for liver and biliary cancer. Semin Surg Oncol 2000; 19: 189.
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al,. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
6. Bechstein WO, Guckelberger O, Kling N, Rayes N, Tullius SG, Lobeck H, et al,. Recurrence-free survival after liver transplantation for small hepatocellular carcinoma. Transpl Int 1998; 11 (Suppl. 1): S189.
7. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al,. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 1001.
8. Llovet JM, Paradis V, Kudo M, Zucman-Rossi J,. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl 2011; 17 (Suppl. 2): S67.
9. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al,. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35.
10. Bartel DP,. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215.
11. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS,. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526.
12. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, et al,. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836.
13. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, et al,. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011; 140: 1618 e16.
14. Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, et al,. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol 2012; 57: 584.
15. Wang J, Li J, Wang X, Zheng C, Ma W,. Downregulation of microRNA-214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis. Biochem Biophys Res Commun 2013; 439: 47.
16. Greene CM, Varley RB, Lawless MW,. MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled. World J Gastroenterol 2013; 19: 5212.
17. Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, et al,. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 2012; 6: 445.
18. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH,. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012; 138: 153.
19. Barry CT, D'Souza M, McCall M, Safadjou S, Ryan C, Kashyap R, et al,. Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant 2012; 12: 428.
20. Borel F, Konstantinova P, Jansen PL,. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371.
21. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289.
22. Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, et al,. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One 2014; 9: e109347.
23. Heagerty PJ, Lumley T, Pepe MS,. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337.
24. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, et al,. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012; 40: W498.
25. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M,. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 1999; 27: 29.
26. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, et al,. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182; discussion 8.
27. Welker MW, Bechstein WO, Zeuzem S, Trojan J,. Recurrent hepatocellular carcinoma after liver transplantation-an emerging clinical challenge. Transpl Int 2013; 26: 109.
28. Otto G, Schuchmann M, Hoppe-Lotichius M, Heise M, Weinmann A, Hansen T, et al,. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol 2013; 59: 279.
29. Seehofer D, Nebrig M, Denecke T, Kroencke T, Weichert W, Stockmann M, et al,. Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis. Clin Transplant 2012; 26: 764.
30. Peveling-Oberhag J, Doring C, Hartmann S, Filmann N, Mertens A, Piiper A, et al,. Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. Clin Sci (Lond) 2015; 128: 29.
31. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al,. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013; 49: 3442.
32. Koberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bonig H, et al,. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One 2013; 8: e75184.
33. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al,. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One 2014; 9: e107986.
34. Xu Y, Bu X, Dai C, Shang C,. High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumour Biol 2015; 36: 4773.
35. Zhang YC, Xu Z, Zhang TF, Wang YL,. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol 2015; 21: 9853.
36. Proneth A, Zeman F, Schlitt HJ, Schnitzbauer AA,. Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis. Ann Surg Oncol 2014; 21: 3096.
37. Seshadri RM, Besur S, Niemeyer DJ, Templin M, McKillop IH, Swan RZ, et al,. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014; 16: 1102.
38. Piardi T, Gheza F, Ellero B, Woehl-Jaegle ML, Ntourakis D, Cantu M, et al,. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 2020.
39. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al,. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61: 1968.
40. Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, et al,. MicroRNA-140 acts as a liver tumor suppressor by controlling NF-kappaB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. Hepatology 2013; 57: 162.
41. Yang H, Fang F, Chang R, Yang L,. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 2013; 58: 205.
42. Bonadio I, Colle I, Geerts A, Smeets P, Berardi G, Praet M, et al,. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience. Clin Transplant 2015; 29: 425.
43. van Mil A, Grundmann S, Goumans MJ, Lei Z, Oerlemans MI, Jaksani S, et al,. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc Res 2012; 93: 655.
44. Cheng AL, Shen YC, Zhu AX,. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology 2011; 81: 372.
45. Xia H, Ooi LL, Hui KM,. MiR-214 targets beta-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One 2012; 7: e44206.
46. Chai J, Wang S, Han D, Dong W, Xie C, Guo H,. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. Tumour Biol 2014; 36: 1313.
47. Tian Y, Hu Y, Wang Z, Chen K, Zhang L, Wang L, et al,. Hepatitis B virus regulates Raf1 expression in HepG2.2.15 cells by enhancing its promoter activity. Arch Virol 2011; 156: 869.
48. Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, et al,. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004; 29: 113.
49. Chakraborty S, Lakshmanan M, Swa HL, Chen J, Zhang X, Ong YS, et al,. An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma. Nat Commun 2015; 6: 6184.
50. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, et al,. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005; 24: 6406.
51. Leung WK, Ching AK, Chan AW, Poon TC, Mian H, Wong AS, et al,. A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 2011; 30: 4464.
52. Zhou X, Zimonjic DB, Park SW, Yang XY, Durkin ME, Popescu NC,. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol 2008; 32: 1285.